playtoearnappscrypto| Shanghai Pharmaceutical (02607.HK): I040 received clinical trial approval notice

Glonghui May 24 丨 Shanghai Pharmaceutical (601607)(02607.HK) announcementplaytoearnappscryptoRecently, the "I040"(hereinafter referred to as the "project") clinical trial application developed by Shanghai Pharmaceutical Group Co., Ltd.(hereinafter referred to as "Shanghai Pharmaceutical" or "Company") received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration (hereinafter referred to as "State Food and Drug Administration").

I040 is a small molecule compound. Preclinical studies have shown that I040 can improve core symptoms in multiple animal models of depression and has better safety.

In August 2020, Shanghai Pharmaceutical signed a technology development agreement with Shanghai Dongxi Zhihui Biomedical Co., Ltd. for the product, according to which Shanghai Pharmaceutical owns full intellectual property rights, development and commercialization rights of the product. As of the disclosure date of this announcement, the project has invested a total of 4%.playtoearnappscrypto, RMB 4.5983 million.

Tags:

Prev: freedrawpokergamesonline| LME metal warehouse receipt dynamics: copper, aluminum, nickel, zinc, lead and tin cancellations reduced by 54 to 3425 tons
Next: playtoearncryptoiosgames| Qibin Group (601636.SH): Holding subsidiary Qibin Solar plans to increase capital by RMB 650 million to Sabah Photovoltaic